Should Race-Genotype Interactions Be Considered in the Global Development of CYP2C19 Substrates? A Proposed Framework Using Physiologically Based Pharmacokinetic Modeling

J Clin Pharmacol. 2017 Apr;57(4):417-421. doi: 10.1002/jcph.859. Epub 2016 Dec 22.

Authors

Chirag Patel¹, Chetan Rathi², Karthik Venkatakrishnan¹

Affiliations

¹ Takeda Pharmaceuticals International Company, Cambridge, MA, USA.
² University of Tennessee Health Science Center, Memphis, TN, USA.

PMID: 28004391
DOI: 10.1002/jcph.859

No abstract available

Keywords: CYP2C19; PBPK; genetic polymorphism; genotype; physiologically based pharmacokinetic modeling; race.

Publication types

Review

MeSH terms

Cytochrome P-450 CYP2C19 / genetics*
Cytochrome P-450 CYP2C19 / metabolism
Cytochrome P-450 CYP2C19 Inducers / metabolism
Cytochrome P-450 CYP2C19 Inducers / pharmacology*
Cytochrome P-450 CYP2C19 Inhibitors / metabolism
Cytochrome P-450 CYP2C19 Inhibitors / pharmacology*
Drug Discovery / methods
Drug Discovery / trends
Genotype*
Humans
Models, Biological*
Racial Groups / genetics*
Substrate Specificity / drug effects
Substrate Specificity / physiology

Substances

Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C19 Inhibitors
CYP2C19 protein, human
Cytochrome P-450 CYP2C19